Invus Public Equities, L.P.

CIK 1340097 · last filed 2024-12-12

Invus Public Equities, L.P. is a corporate insider who has filed 9 SEC Form 4 insider transactions across 3 companies since 2018. The most recent filing shows the insider sold $333.2M of SRRK on Dec 12, 2024. Across all open-market trades the lifetime net is −$307.9M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $548.4M across reported positions. The firm reports its address in New York, NY. 52 SEC filings were submitted jointly with Invus Public Equities Advisors, LLC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$548.37M

Companies

3

Total Filings

9

Lifetime Open-Market Net

-$307.87M

Filer Profile

Reported Address
C/O THE INVUS GROUP, LLC
750 LEXINGTON AVENUE, 30TH FLOOR
NEW YORK, NY 10022
Phone
(212) 317-7520
Formerly Known As
Invus Public Equities, LP (2005–2012)
Related Filers
Invus Public Equities Advisors, LLC — 52 joint filings, latest 2024-12-12
Artal Group S.A. — 40 joint filings, latest 2024-05-14
Artal International Management S.A. — 40 joint filings, latest 2024-05-14
International S.C.A. Artal — 40 joint filings, latest 2024-05-14
Administratiekantoor Westend Stichting — 40 joint filings, latest 2024-05-14
Westend S.A. — 40 joint filings, latest 2024-05-14
Invus Advisors, L.L.C. — 20 joint filings, latest 2024-05-14
Invus, L.P. — 20 joint filings, latest 2024-05-14
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
SRRK 10%+ Owner 9,700,005 $55.41 $537.48M -$160.57M 5 2024-12-12
CRESCENT BIOPHARMA, INC. (GLYC) Delisted 10%+ Owner 66,957 $15.70 $1.05M -$1.49M 3 2024-08-07
SEER 10%+ Owner 5,588,366 $1.95 $10.90M -$145.81M 1 2021-02-03

Recent Filings

9 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2024-12-12 SRRK Sell (S) −8,000,000 -$333.20M EDGAR
2024-08-07 CRESCENT BIOPHARMA, INC. (GLYC) Delisted Sell (S) −1,101,275 -$205.9K EDGAR
2024-07-30 CRESCENT BIOPHARMA, INC. (GLYC) Delisted Sell (S) −6,895,595 -$1.58M EDGAR
2023-10-16 SRRK Buy (P) +17,599,448 $120.69M EDGAR
2023-05-02 SRRK Buy (P) +252,456 $1.62M EDGAR
2023-02-13 CRESCENT BIOPHARMA, INC. (GLYC) Delisted Buy (P) +91,608 $297.0K EDGAR
2023-01-11 SRRK Sell (S) −8,752 -$83.0K EDGAR
2021-02-03 SEER Sell (S) −2,272,905 -$145.81M EDGAR
2018-05-31 SRRK Mixed +19,168,320 $50.40M EDGAR
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.